Dr. Anna Marusiak graduated from the University of Wrocław in the field of medical biotechnology. She completed the PhD course at the University of Birmingham. During 2011-2015 she was a postdoctoral fellow at the Cancer Research UK Manchester Institute. In 2015 dr. Marusiak joined the Laboratory of Experimental Medicine at the Centre of New Technologies, University of Warsaw, where she was a project leader of three grants (Fuga, Homing, Sonata). Currently, she is a group leader at IMol PAS within the framework of ReMedy project.

THE SCOPE OF THE RESEARCH

The group is interested in cancer biology, cellular signalling during oncogenesis and the identification of novel targets for cancer therapies. The main aim of the research is to identify the molecular processes responsible for the development and progression of cancer and to use that knowledge to design novel anticancer treatments. Currently, the group  focuses on investigating the oncogenic signalling activated by MLK4 in breast cancer and uncovering the importance of MLK4-dependent cross-talk signalling between tumour microenvironment and breast cancer cells.